Literature DB >> 25588354

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Heather E Allen Reish1, David G Standaert1.   

Abstract

Alpha-synuclein (α-syn) is central to the pathogenesis of Parkinson disease (PD). Gene duplications, triplications and point mutations in SNCA1, the gene encoding α-syn, cause autosomal dominant forms of PD. Aggregated and post-translationally modified forms of α-syn are present in Lewy bodies and Lewy neurites in both sporadic and familial PD, and recent work has emphasized the prion-like ability of aggregated α-syn to produce spreading pathology. Accumulation of abnormal forms of α-syn is a trigger for PD, but recent evidence suggests that much of the downstream neurodegeneration may result from inflammatory responses. Components of both the innate and adaptive immune systems are activated in PD, and influencing interactions between innate and adaptive immune components has been shown to modify the pathological process in animal models of PD. Understanding the relationship between α-syn and subsequent inflammation may reveal novel targets for neuroprotective interventions. In this review, we examine the role of α-syn and modified forms of this protein in the initiation of innate and adaptive immune responses.

Entities:  

Keywords:  Parkinson disease; T-lymphocyte; adaptive immunity; alpha-synuclein; antigen presentation; innate immunity; microglia; post-translational modifications

Mesh:

Substances:

Year:  2015        PMID: 25588354      PMCID: PMC4405142          DOI: 10.3233/JPD-140491

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  231 in total

1.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

2.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.

Authors:  Y He; S Appel; W Le
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

3.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

4.  The regulation of synaptic function by alpha-synuclein.

Authors:  Serena Bellani; Vitor L Sousa; Giuseppe Ronzitti; Flavia Valtorta; Jacopo Meldolesi; Evelina Chieregatti
Journal:  Commun Integr Biol       Date:  2010-03

5.  MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.

Authors:  I Kurkowska-Jastrzebska; A Wrońska; M Kohutnicka; A Członkowski; A Członkowska
Journal:  Acta Neurobiol Exp (Wars)       Date:  1999       Impact factor: 1.579

Review 6.  Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors:  Joshua J Gagne; Melinda C Power
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

7.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

8.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

9.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice.

Authors:  Sachiko Tanaka; Atsuko Ishii; Hirokazu Ohtaki; Seiji Shioda; Takemi Yoshida; Satoshi Numazawa
Journal:  J Neuroinflammation       Date:  2013-12-01       Impact factor: 8.322

View more
  80 in total

1.  microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.

Authors:  Aaron D Thome; Ashley S Harms; Laura A Volpicelli-Daley; David G Standaert
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

Review 2.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

Review 3.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

4.  Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.

Authors:  Zachary A Sorrentino; Yuxing Xia; Cory Funk; Cara J Riffe; Nicola J Rutherford; Carolina Ceballos Diaz; Amanda N Sacino; Nathan D Price; Todd E Golde; Benoit I Giasson; Paramita Chakrabarty
Journal:  Neurobiol Dis       Date:  2018-09-06       Impact factor: 5.996

Review 5.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

Review 6.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

7.  Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.

Authors:  Joseph Webb; Auriel A Willette
Journal:  Neurobiol Aging       Date:  2016-10-13       Impact factor: 4.673

8.  Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Authors:  Viviane Labrie; Patrik Brundin
Journal:  J Innate Immun       Date:  2017-09-02       Impact factor: 7.349

9.  TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models.

Authors:  Ying Guo; Xinbing Wei; Hua Yan; Yue Qin; Shaoqi Yan; Jia Liu; Yong Zhao; Fan Jiang; Haiyan Lou
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

10.  Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles.

Authors:  Adam Labadorf; Seung H Choi; Richard H Myers
Journal:  Front Mol Neurosci       Date:  2018-01-11       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.